Selcia Limited, an Essex-based contract research organisation, has announced a new drug discovery collaboration agreement with Gilead Sciences, Inc. of California.
It builds on an established partnership following significant progress made to date. Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.
Dr William Lee, senior vice-president for research at Gilead Sciences, said: “This is a very important therapeutic area for Gilead. Scientists from both companies have interacted well together and have made successful progress against some difficult targets.
“We are looking forward to the collaboration delivering candidates for clinical studies in the foreseeable future.”
Selcia MD, Dr Hans Fliri added: “We are delighted to build on our strong collaborative relationship with Gilead in this challenging research area and important therapeutic indication.
“This represents a significant step forward in the development of Selcia’s discovery services and further cements our position as a strategic and trusted partner for integrated drug discovery.”
Selcia is a privately held CRO with two operating divisions, Selcia Discovery and Selcia Radiolabelling, operating from a modern facility in Ongar.